INDOX has facilitated the participation of collaborating centres in phases I, II and III trials in all common cancers, with an emphasis on those cancers which are more prevalent in India. A total of 34 trial protocols have been submitted to the Network by multiple collaborators. Approximately 300 patients have been recruited through the network into phase I-III trials in head and neck, breast, colorectal, renal, cervical, lung and leukemia cancers.
INDOX are also conducting a series of epidemiological research studies, to investigate the common causes of cancers in Indian populations and low cost methods of treatment.
Ongoing INDOX sponsored research studies include:
- ASCOLT - Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers; an international, multi-centre, double blind, randomised placebo controlled Phase III Trial.
- INDOX Case-Control Consortium - a series of studies investigating risk factors for common cancers in Indian populations.
- A comparison of cancer incidence rates in Indian and Pakistani migrants to the UK to rates among whites and rates in India and Pakistan.
- A study of the consistency of reporting of breast pathology in the INDOX network.
Over the next five years, INDOX would like to support the work of Indian and Oxford researchers in those areas that are of the greatest need in India, but are not currently being addressed, such as:
- Research into the causes of common cancers in Indian populations.
- Research into the impact of cancer prevention measures where resources are limited, such as low-cost screening programmes and educational programmes.
- Research into the effectiveness of treatments which will be affordable to the majority of the Indian population, including traditional ayurvedic medicines.
INDOX is also planning a major cohort study to investigate the effects of diet and lifestyle on the risk of common diseases (particularly cancer but also ischaemic heart disease, diabetes and stroke) in people of South Asian origin in the UK.
If you would like to make a contribution to INDOX's research, we would welcome your support.